Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L

Molecular Pharmacology

Volumn 74, Issue 1, 2008, Pages 34-41

  Shah, Parag P ^a   Myers, Michael C ^a   Beavers, Mary Pat ^a   Purvis, Jeremy E ^a   Jing, Huiyan ^a   Grieser, Heather J ^b   Sharlow, Elizabeth R ^b   Napper, Andrew D ^a   Huryn, Donna M ^a   Cooperman, Barry S ^a   Smith III, Amos B ^a   Diamond, Scott L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN G; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CATHEPSIN V; CLIK 148; CYSTEINE PROTEINASE INHIBITOR; PAPAIN; S [2 [(2 ETHYLPHENYL)AMINO] 2 OXOETHYL][2 [3 (1H INDOL 3 YL) 2 [(2 METHYLPROPAN 2 YL)OXYCARBONYLAMINO]PROPANOYL]HYDRAZINYL]METHANETHIOATE; SID 26681509;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HYDROGEN BOND; LEISHMANIA MAJOR; MOLECULAR DOCKING; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; AORTA; BINDING SITES; CATHEPSINS; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; KINETICS; LEISHMANIA MAJOR; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PAPAIN; PLASMODIUM FALCIPARUM; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY;

EID: 45749118726     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.046219     Document Type: Article

References (25)

1. Baggio R, Shi YQ, Wu YQ, and Abeles RH (1996) From good substrates to good inhibitors: design of inhibitors for serine and thiol proteases. Biochemistry 35: 3351-3353.
2. Chandran K, Sullivan NJ, Felbor U, Whelan SP, and Cunningham JM (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645.
3. Choe Y, Leonetti F, Greenbaum DC, Lecaille F, Bogyo M, Bromme D, Ellman JA, and Craik CS (2006) Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem 281: 12824-12832.
4. Copeland RA (2005) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. J. Wiley, Hoboken, NJ.
5. Fujishima A, Imai Y, Nomura T, Fujisawa Y, Yamamoto Y, and Sugawara T (1997) The crystal structure of human cathepsin L complexed with E-64. FEBS Lett 407:47-50.
6. Griffin JD and Kolda TG (2006) Asynchronous Parallel Generating Set Search for Linearly-Constrained Optimization. Sandia National Laboratories, Livermore, CA.
7. Hagemann S, Günther T, Dennemärker J, Lohmüller T, Bromme D, Schule R, Peters C, and Reinheckel T (2004) The human cysteine protease cathepsin V can compensate for murine cathepsin L in mouse epidermis and hair follicles. Eur J Cell Biol 83:775-780.
8. Katunuma N, Murata E, Kakegawa H, Matsui A, Tsuzuki H, Tsuge H, Turk D, Turk V, Fukushima M, Tada Y, et al. (1999) Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. FEBS Lett 458:6-10.
9. LaLonde JM, Zhao B, Smith WW, Janson CA, DesJarlais RL, Tomaszek TA, Carr TJ, Thompson SK, Oh HJ, Yamashita DS, et al. (1998) Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S′-subsites. J Med Chem 41:4567-4576.
10. Leist M and Jaattela M (2001) Triggering of apoptosis by cathepsins. Cell Death Differ 8:324-326.
11. Magrath J and Abeles RH (1992) Cysteine protease inhibition by azapeptide esters. J Med Chem 35:4279-4283.
12. Myers MC, Shah PP, Diamond SL, Huryn DM, and Smith AB III (2008) Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor. Bioorg Med Chem Lett 18:210-214.
13. Nägler DK and Menard R (2003) Family C1 cysteine proteases: biological diversity or redundancy? Biol Chem 384:837-843.
14. Nomura T and Katunuma N (2005) Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 52:1-9.
15. Otto HH and Schirmeister T (1997) Cysteine Proteases and Their Inhibitors. Chem Rev 97:133-172.
16. Pager CT and Dutch RE (2005) Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J Virol 79:12714-12720.
17. Perola E, Walters WP, and Charifson PS (2004) A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 56:235-249.
18. Reinheckel T, Deussing J, Roth W, and Peters C (2001) Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol Chem 382:735-741.
19. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, and Bates P (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A 102:11876-11881.
20. Thompson SK, Halbert SM, Bossard MJ, Tomaszek TA, Levy MA, Zhao B, Smith WW, Abdel-Meguid SS, Janson CA, D'Alessio KJ, et al. (1997) Design of potent and selective human cathepsin K inhibitors that span the active site. Proc Natl Acad Sci U S A 94:14249-14254.
21. Tsuge H, Nishimura T, Tada Y, Asao T, Turk D, Turk V, and Katunuma N (1999) Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex. Biochem Biophys Res Commun 266:411-416.
22. Turk D and Guncar G (2003) Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr 59:203-213.
23. Turk V, Turk B, and Turk D (2001) Lysosomal cysteine proteases: facts and opportunities. EMBO J 20:4629-4633.
24. Xing R and Hanzlik RP (1998) Azapeptides as inhibitors and active site titrants for cysteine proteinases. J Med Chem 41:1344-1351.
25. Zhang JH, Chung TD, and Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73.